Loading...
Please wait, while we are loading the content...
Similar Documents
Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Nagane, Motoo Kobayashi, Keiichi Ohnishi, Akiko Shimizu, Saki Shiokawa, Yoshiaki |
| Copyright Year | 2007 |
| Abstract | BACKGROUND Temozolomide (TMZ) is active against newly diagnosed glioblastoma (GBM), and O(6)-methylguanine-DNA methyltransferase (MGMT) is implicated in resistance to TMZ and nitrosoureas. We evaluated the efficacy and safety of the standard 5-day TMZ regimen in patients with recurrent GBM after initial therapy including nitrosourea-based chemotherapy, in conjunction with an analysis of the prognostic value of MGMT protein expression regarding response to TMZ and survival. METHODS From September 2003 to January 2007, 30 patients having recurrent GBM received 150-200 mg/m(2)/day of TMZ for five consecutive days every 28 days. Tumor tissue from 19 patients was analysed for MGMT protein expression using western blotting, and 17 of them were assessable for a response. RESULTS The overall response rate was 23.5% (one complete response and three partial responses). Six patients had stable disease (35.3%). Median progression-free survival (PFS) time was 2.2 months, and median overall survival (OS) time was 9.9 months from the initiation of TMZ therapy. Patients with low MGMT protein expression had a significantly improved PFS (P = 0.016) and OS (P = 0.019) compared to those with high expression. Both low MGMT expression (P = 0.040) and re-resection at relapse (P = 0.014) persisted as significant independent favorable prognostic factors for OS. The most common grade 3 and 4 hematological toxicity was lymphopenia (22.2%). CONCLUSIONS The standard 5-day TMZ regimen resulted in moderate antitumor activity with an acceptable safety profile in patients with nitrosourea-pretreated recurrent GBM, and protein expression of MGMT is an important prognostic factor for patients treated with TMZ even after recurrence. |
| Starting Page | 897 |
| Ending Page | 906 |
| Page Count | 10 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://jjco.oxfordjournals.org/content/early/2007/12/21/jjco.hym132.full.pdf |
| Alternate Webpage(s) | http://citeseerx.ist.psu.edu/viewdoc/download;jsessionid=EACC788B4E6A9157FAD1E708A26E6FCD?doi=10.1.1.316.3623&rep=rep1&type=pdf |
| PubMed reference number | 18156172v1 |
| Volume Number | 37 |
| Issue Number | 12 |
| Journal | Japanese journal of clinical oncology |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Adverse reaction to drug Excision Lymphopenia Neoplasms Nitrosourea Compounds O(6)-Methylguanine-DNA Methyltransferase O-(6)-methylguanine Overall Survival Patients Prognostic Factors Progression-Free Survival Recurrent Glioblastoma Transcription Initiation Western Blotting pediatric intracranial germ cell brain tumor protein expression temozolomide |
| Content Type | Text |
| Resource Type | Article |
